ArticleOncology research2025
Hypoxia-induced exosomal lncRNA-PVT1 as a biomarker and mediator of EMT in hepatocellular carcinoma.
Article in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unraveling the role of LINC02657 in clear cell renal cell carcinoma: insights into tumor aggression, immune modulation, and treatment response.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Exosomal long noncoding RNAs (lncRNAs) might facilitate epithelial-mesenchymal transition (EMT) in liver cancer after transarterial chemoembolization (TACE), thereby enhancing tumor cell invasiveness and migration. This study investigated the prognostic role of plasma exosomal long noncoding RNA-plasmacytoma variant translocation 1 (lncRNA-PVT1) in TACE treated hepatocellular carcinoma (HCC). Methods: Plasma exosomal lncRNA-PVT1 was evaluated via qPCR before and after TACE. Hepatoma cell behavior was investigated in different HCC cell lines. A lncRNA-PVT1 plasmid was synthesized and overexpressed, and si-lncRNA PVT1 was transfected into poorly invasive cells to reveal its influence on cell characteristics. The lncRNA-PVT1-FoxM1 interaction was elucidated using a double-luciferase reporter gene assay. The effect of miRNA-345-5p on minimally invasive hepatoma cells was assessed. Three experimental groups were established: poorly invasive cells, poorly invasive cells co-cultured with exosomes from hypoxia-induced highly invasive cells, and poorly invasive cells co-cultured with normal hepatocyte exosomes. Liver cancer cells were subcutaneously inoculated into nude mice, with subsequent observations of weight, tumor formation, and tumor size. Results: We identified two lncRNAs (lncRNA-PVT1 and GAPLINC) associated with EMT in the hypoxic microenvironment of liver cancer. Cox multivariate regression analysis was used to establish a prognostic model distinguishing high- and low-risk groups. Hypoxia-induced HepG2 exosomes significantly promoted EMT in poorly invasive HCC cells. LncRNA-PVT1 overexpression and silencing altered E-cadherin, vimentin, and FoxM1 expression, cell proliferation, invasion, migration, and apoptosis. miR-345-5p directly targeted lncRNA-PVT1 and FoxM1, affecting downstream targets. Conclusions: Plasma exosomal lncRNA-PVT1 expression is upregulated in highly invasive cells post-hypoxia, potentially serving as a biomarker for evaluating liver cancer prognosis after TACE. Through a miRNA-345-5p-mediated competing endogenous RNA mechanism, it promotes EMT in poorly invasive cells, likely contributing to recurrence and metastasis post-HCC interventional embolization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.